Sage Therapeutics, Inc.
sagerx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Jul 30, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 14, 2025.
10-Q for Q2 FY2025, filed Jul 30, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sells an oral treatment for postpartum depression and develops drug candidates for brain disorders, including neurodevelopmental and neuropsychiatric conditions.
10-K for FY2024, filed Feb 11, 2025We are a biopharmaceutical company with a mission to pioneer solutions to deliver life-changing brain health medicines, so every person can…View ↗
Our product ZURZUVAE® (zuranolone) was approved by the U.S. Food and Drug Administration, or FDA, in August 2023 for the treatment of PPD…View ↗
We expect to continue to focus on the development of product candidates for the treatment of both acute and chronic brain health disorders…View ↗
Who Were Their Customers?
Women with postpartum depression receive ZURZUVAE through specialty pharmacies, which ship it directly after healthcare professionals prescribe it; Sage and Biogen jointly market the treatment.
10-K for FY2024, filed Feb 11, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Jul 30, 2025
−$49.7MView ↗
- ▼ −52% (Loss)
- vs −$102.9M in Q2 FY2024
10-Q for Q2 FY2025, filed Jul 30, 2025
Open tableView ↗
-
Jul 31, 2025
Sage’s merger changed control and prompted delisting
All prior officers ceased to serve, and the company asked Nasdaq to remove its shares from listing.
Sources
8-K, filed Jul 31, 2025
On July 30, 2025, the Company notified the Nasdaq Stock Market LLC (“Nasdaq”) of the anticipated consummation of the transactions and…View ↗
Commercial product
The earlier report presented ZULRESSO as Sage’s first product and zuranolone as a candidate; the latest describes ZURZUVAE as marketed and ZULRESSO as discontinued.
10-K for FY2021, filed Feb 24, 2022 10-K for FY2024, filed Feb 11, 2025We are a biopharmaceutical company committed to developing and commercializing novel medicines with the potential to transform the lives of…View ↗
Our first product, ZULRESSO, is a proprietary intravenous, or IV, formulation of brexanolone, approved in the U.S. as a treatment for PPD…View ↗
Our next most advanced product candidate is zuranolone (SAGE-217), a novel oral compound being developed for certain affective disorders…View ↗
Pipeline emphasis
The earlier report highlighted a compound for cognition-related disorders; the latest highlights a candidate for behavioral symptoms and a focus on neurodevelopmental disorders.
10-K for FY2021, filed Feb 24, 2022 10-K for FY2024, filed Feb 11, 2025Our second area of focus for development is novel compounds that target the NMDA receptor. Our lead product candidate selected in this area…View ↗
Who Did They Compete With?
Competes with Lipocine, Brii Biosciences, Marinus Pharmaceuticals, and Cerevel Therapeutics
10-K for FY2024, filed Feb 11, 2025Currently, the only pharmacological therapies specifically approved for the treatment of PPD are ZURZUVAE and ZULRESSO. We discontinued…View ↗
Loading...
